A new pill called daraxonrasib nearly doubled survival in advanced pancreatic cancer patients The drug targets mutated KRAS proteins found in over 90% of pancreatic cancer cases Study showed median survival of 13.2 months with the pill versus 6.7 months with chemotherapy